These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22507911)

  • 21. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphenol A in chronic kidney disease.
    Krieter DH; Canaud B; Lemke HD; Rodriguez A; Morgenroth A; von Appen K; Dragoun GP; Wanner C
    Artif Organs; 2013 Mar; 37(3):283-90. PubMed ID: 23145999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does an alteration of dialyzer design and geometry affect biocompatibility parameters?
    Opatrný K; Krouzzecký A; Polanská K; Mares J; Tomsů M; Bowry SK; Vienken J
    Hemodial Int; 2006 Apr; 10(2):201-8. PubMed ID: 16623675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
    Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
    Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do clinical outcomes in chronic hemodialysis depend on the choice of a dialyzer?
    Ward RA
    Semin Dial; 2011; 24(1):65-71. PubMed ID: 21323999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure.
    Matsumoto A; Hirata Y; Kakoki M; Nagata D; Momomura Si; Sugimoto T; Tagawa H; Omata M
    Clin Sci (Lond); 1999 Jan; 96(1):67-74. PubMed ID: 9857108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vitamin K1 and C metabolism in uremia during hemodialysis].
    Bakaev VV; Khomenko VF
    Urol Nefrol (Mosk); 1991; (1):40-3. PubMed ID: 1858205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breath analysis in patients with end-stage renal disease: effect of haemodialysis.
    Rolla G; Bruno M; Bommarito L; Heffler E; Ferrero N; Petrarulo M; Bagnis C; Bugiani M; Guida G
    Eur J Clin Invest; 2008 Oct; 38(10):728-33. PubMed ID: 18837798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
    Moriishi M; Kawanishi H; Tsuchiya S
    Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dialysis purity on uremic dyslipidemia.
    Schiffl H; Lang SM
    Ther Apher Dial; 2010 Feb; 14(1):5-11. PubMed ID: 20438514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Red blood cell survival in long-term dialysis patients.
    Vos FE; Schollum JB; Coulter CV; Doyle TC; Duffull SB; Walker RJ
    Am J Kidney Dis; 2011 Oct; 58(4):591-8. PubMed ID: 21715072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining dialysate and blood recirculation to boost uremic toxin removal: theory and simulation study.
    Prado M; Roa L
    Artif Organs; 2007 Dec; 31(12):895-901. PubMed ID: 17924986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with short-time hemodialysis.
    Kes P; Ratković-Gusić I
    Acta Med Croatica; 1995; 49(2):53-8. PubMed ID: 7580039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress in hemodialysis--postdialytic changes.
    Dakshinamurty KV; Rao PV; Saibaba KS; Sheela RB; Sreekrishna V; Venakataramana G; Shyam C; Jayaseelan L
    Clin Lab; 2003; 49(5-6):255-61. PubMed ID: 15285183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality.
    Korevaar JC; van Manen JG; Dekker FW; de Waart DR; Boeschoten EW; Krediet RT;
    J Am Soc Nephrol; 2004 Nov; 15(11):2916-22. PubMed ID: 15504945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
    Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
    J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.